Abstracts Archive - Page 571 of 1683 - ATC Abstracts

2019 American Transplant Congress
Policy Changes in Liver Graft Allocation for Hepatocellular Carcinoma in the USA: Improved Survival for African American Recipients
M. Molinari¹, D. Jorgensen¹, A. Tevar¹, C. Hughes¹, A. Humar¹, N. Jonassaint²
¹Surgery, University of Pittsburgh Medical Centre, Pittsburgh, PA, ²Medicine, University of Pittsburgh Medical Centre, Pittsburgh, PA
*Purpose: To evaluate the effect of policy changes in liver graft allocation for hepatocellular carcinoma (HCC) on the overall survival of patients of different ethnicities…
2019 American Transplant Congress
Long Term Impact of Intraoperative Autologous Blood Transfusion on HCC Recurrence in Liver Transplantation
G. Kelly¹, J. L. Pasko¹, E. Dewey², E. Maynard¹, S. L. Orloff¹, C. Enestvedt¹
¹Division of Abdominal Transplant, OHSU, Portland, OR, ²Department of General Surgery, OHSU, Portland, OR
*Purpose: The aim of this study was to determine whether intraoperative autologous transfusion in liver transplant patients with HCC affects the rate of recurrence.*Methods: We…
2019 American Transplant Congress
Outcome Of Living Donor Liver Transplantation In Elderly Patients >65 Years With And Without Hepatocellular Carcinomas: A Retroepsective Analysis
A. Thorat, L. Jeng, S. Hsu, H. Yang, C. Yeh, T. Chen, K. Poon, P. Li
Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan
*Purpose: The elderly patients > 65 years with end-stage liver disease that require liver transplantation has been steadily increased over last decade in Taiwan and…
2019 American Transplant Congress
Favorable Outcome of Pathologic Downstaging by Locoregional Treatment for Hepatocellular Carcinoma in Liver Transplantation
D. Kim, J. Lee, S. Kim, K. In, D. Joo, S. Kim, M. Kim
Severance hospital, Seoul, Korea, Republic of
*Purpose: There was no distinct guideline how to take into account the effect of pretransplant locoregional treatment (LRT) in hepatocellular carcinoma (HCC) staging system. The…
2019 American Transplant Congress
Tumor Necrosis as a Result to Pre-Transplant Bridging Treatment for Hepatocellular Carcinoma and Its Effect on Post-Transplant Outcome
S. Radunz¹, A. Kirschner¹, J. M. Theysohn², C. Schotten³, T. Benkö¹
¹General, Visceral and Transplant Surgery, University Hospital Essen, Essen, Germany, ²Diagnostic and Interventional Radiology and Neurradiology, University Hospital Essen, Essen, Germany, ³Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany
*Purpose: As a bridge to liver transplantation, locoregional treatments are commonly employed in hepatocellular carcinoma (HCC) patients to prevent tumor progression during waiting time. Objective…
2019 American Transplant Congress
Resource Utilization in Hepatocellular Carcinoma Liver Transplantation before and after the Six Month Wait Time
J. Sokolich¹, W. McClellan², J. Buggs¹, E. Rogers¹, K. Barber¹, K. Cocuy¹, A. Kumar²
¹Tampa General Hospital, Tampa, FL, ²University of South Florida, Tampa, FL
*Purpose: The purpose of this study was to determine any difference in resource utilization since the implementation of the mandatory six month wait-time policy for…
2019 American Transplant Congress
Hepatocellular Carcinoma in Fontan Liver Disease
V. Lamm¹, J. Wedd², C. Haydek², C. Obineme², A. Noll², H. Veeramachaneni², M. Muftah², R. Ford²
¹Internal Medicine, Emory, Atlanta, GA, ²Emory, Atlanta, GA
*Purpose: To add to the clinical characteristics and outcomes of hepatocellular carcinoma (HCC) in post Fontan operation patients and present, to the best of our…
2019 American Transplant Congress
Clinical Presentation After Hepatitis B Recurrence In Liver Transplant Patients
W. Lee, C. Cheng, T. Wu, Y. Wang, C. Lee, T. Wu, H. Chou, K. Chan
Chang-Gung Hospital, Taoyuan, Taiwan
*Purpose: Combination of anti-hepatitis B immunoglobulin and antiviral agents is the standard care for prophylaxis of hepatitis B virus (HBV) recurrence after liver transplantation. However,…
2019 American Transplant Congress
Rituximab Desensitization to Liver Transplantaiton Recipients with Preformed Donor Specific Antibodies to Prevent Antibody Mediated Rejecton
Y. Ogura, M. Shizuku, N. Kurata, K. Jobara, H. Kamei
Transplantation Surgery, Nagoya University Hospital, Nagoya City, Japan
*Purpose: Preformed donor-specific antibodies (DSA) are considered as a risk factor after solid organ transplantation. Strong DSA is associated with high mortality and increased risk…
2019 American Transplant Congress
Donor Lymphocyte Chimerism and Homozygosity Are Critical Indicators for Timely and Accurate Diagnosis of Acute Graft vs. Host Disease after Liver Transplantation
A. Zhang, B. Eghtesad
Cleveland Clinic Foundation, Cleveland, OH
*Purpose: The mortality of Acute Graft vs. Host Disease (aGvHD) after Liver Transplantation (LT) can be greater than 85% due to delays in diagnosis and…